What is Bromazolam?
Bromazolam was first synthesized back in 1976, but was never commercially marketed and not identified until much later in the early 2000’s by the EMCDDA in Sweden.
Also known as 8-bromo-6-phenyl-1-methyl-4H-benzo[f] [1,2,4]triazolo[4,3-a] [1,4]diazepine or XLI-268,
It shares the most of its structural properties with Alprazolam (brand name Xanax) and this is reflected in the anxiolytic and sedative effects that reported in laboratory studies.
A fairly substantial amount of information about Bromazolam and its effects is reported in studies found on internet forums, however, regarding future legality and possible inclusion in the Opium Act remains unclear.
For now, it remains legal in much of Europe, so at Multiple Scaners we are happy to offer laboratory-grade Powder and 3mg Bromazolam Pellets for your research purposes.
Safety Measures for Bromazolam
Due to its potency and associated side effects, it’s recommended that gloves, eyewear, and respirators are used when handling the Powder in the lab.
Bromazolam Pellets, however, are considerably more stable but great caution should always be taken with this novel compound.
In the event of accidental exposure, it is recommended to show the product label (containing the IUPAC information) to the medical professionals. Accidental contact with the eyes should be treated swiftly by thorough rinsing with water after the removal of contact lenses.
How to Store?
Like any compounds, there are things to avoid when storing the Powder or the Pellets such as; Direct sunlight, excessive humidity and moisture.
Bromazolam (XLI-268) is a triazolobenzodiazepine (TBZD) which was first synthesised in 1976, but was never marketed.It has subsequently been sold as a designer drug, first being definitively identified by the EMCDDA in Sweden in 2016. It is the bromo instead of chloro analogue of alprazolam and has similar sedative and anxiolytic effects to it and other benzodiazepines. Bromazolam is a non subtype selective agonist at the benzodiazepine site of GABAA receptors, with a binding affinity of 2.81nM at the α1 subtype, 0.69nM at α2 and 0.62nM at α5